Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

NCT01229644 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Arog Pharmaceuticals, Inc.